In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis
NCT ID: NCT02852850
Last Updated: 2016-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of Novel Fecal Microbial Biomarkers for Inflammatory Bowel Disease
NCT05598489
Critical State of "Remission-Recurrence" of Ulcerative Colitis
NCT06694883
Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With Inflammatory Bowel Disease Progression
NCT06995170
Artificial Intelligence System Based on Raman Spectroscopy in Inflammatory Bowel Disease
NCT04888299
Non Invasive Characterization of Pediatric Inflammatory Bowel Diseases Using Multispectral Optoacoustic Tomography
NCT04650867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Molecular Imaging With IFX-FITC
Endoscopic examination with the fluorescent antibody (IFX-FITC) was performed in patients with active ulcerative colitis before infliximab therapy was initiated. Labeled infliximab was applied topically via a standard spray catheter onto the most inflamed region of the bowel during colonoscopy, followed by CLE. In vivo imaging of inflamed areas of the intestinal mucosa showed a specific fluorescence signal of mTNF+ cells after topical application of labeled adalimumab. These specific fluorescence signals were recorded.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with short bowel syndrome.
* Patients during the pregnancy and lactation period.
* Patients received enema therapy within 1 month before inclusion in the study, or had anti-TNF therapy within the last 12 months.
* Patients participated in another clinical trial or administrated other investigational drugs within 4 months prior to the screening visit.
* Patients with moderate to severe heart failure, active tuberculosis or acute infections.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanqing Li
Vice president of Qilu Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yanqing Li, MD,PHD
Role: STUDY_DIRECTOR
Qilu Hospital of Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gastroenterology, Qilu Hospital, Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016SDU-QILU-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.